Your browser doesn't support javascript.
loading
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status.
Casale, Thomas B; Gimenez-Arnau, Ana Maria; Bernstein, Jonathan A; Holden, Michael; Zuberbier, Torsten; Maurer, Marcus.
Afiliación
  • Casale TB; Internal Medicine, Division of Allergy and Immunology, Morsani College of Medicine, University of South Florida, Tampa, FL, 33620, USA. tbcasale@usf.edu.
  • Gimenez-Arnau AM; Dermatology Department, Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Bernstein JA; Department of Medicine, Division of Immunology Allergy Section, University of Cincinnati, Cincinnati, OH, USA.
  • Holden M; Genentech, Inc., South San Francisco, CA, USA.
  • Zuberbier T; Institute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Maurer M; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
Dermatol Ther (Heidelb) ; 13(11): 2573-2588, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37776480
Chronic spontaneous urticaria is a skin condition that causes raised red itchy bumps (known as hives) that appear on the skin on most days for 6 weeks or longer. The hives may be big or small, may be warm to touch, may come and go, and may affect a person's quality of life. Omalizumab is a treatment for people living with chronic spontaneous urticaria that can stop the appearance of hives. This article summarizes all the information that we know about omalizumab for chronic spontaneous urticaria, such as how it works, how successful it is at improving hives, how long it takes to work, how it makes patients feel, and how safe it is. The information in this article shows that omalizumab is helpful for many people with chronic spontaneous urticaria.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos